ASTRO 2025

ASTRO 2025 Annual Meeting

Questions discussed in this category

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?

I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage? This question is par...

2 Answers available

How do molecular and clinical factors guide personalized selection of HSRT dose fractionation regimens with bevacizumab in recurrent high-grade gliomas?

Multivariate analysis identified HSRT dose fractionation, tumor grade, IDH mutation, and 1p/19q codeletion as significant predictors of PFS- do these ...

1 Answer available

How do you balance short-term efficacy against increased low-grade toxicity and quality-of-life considerations for higher single-fraction regimens in recurrent glioma patients?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...

1 Answer available

How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...

1 Answer available

In a patient undergoing neoadjuvant 177Lu-PNT2002 + MDT for oligorecurrent prostate cancer as per the LUNAR trial, what are the implications for other escalated systemic therapies with ARPIs/chemotherapy, which may otherwise be used concurrent with ADT in this population?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...

1 Answer available

Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?

Further radioligand therapy upon disease progression? If proceeding with further RLT, how many cycles may be planned? This question is part o...

1 Answer available

How do you account for dosimetric contributions from 177Lu-PNT2002 when planning SBRT?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...

1 Answer available

Does the choice of radiation modality (3D, IMRT/VMAT, protons) impact the effectiveness of the reduced dose of 20 Gy in DLBCL?

Would you prefer certain modalities if using the lower dose? This question is part of our collaboration with ASTRO 2025 to highlight impactfu...

1 Answer available

What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?

Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups? This question is part of our c...

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2010-11-01

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

American journal of clinical oncology, 2016-02

Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.

Radiother Oncol, 2013-01-01

Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.

The New England journal of medicine, 2011-07-14

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

The Lancet. Oncology, 2018-11

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

J Clin Oncol, 2021 Jan 26

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

Int J Radiat Oncol Biol Phys,

Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.

International journal of radiation oncology, biology, physics, 2025 Feb 22

Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.

BMC Cancer, 2020 Jun 1

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

The Lancet. Oncology, 2025 Mar

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

The Lancet. Oncology, 2025 Mar

Destroy or delay: hormonal therapy in oligometastatic prostate cancer.

Acta neurochirurgica, 2021 Apr 02

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.

The New England journal of medicine, 2017-02-02

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

The New England journal of medicine, 2018-07-12

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

JAMA oncology, 2017-12-01

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Lancet Oncol, 2019 Oct 16

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

N Engl J Med, 2021 Dec 01

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

Lancet,

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019 Sep 12

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Lancet (London, England), 2024 May 16

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.

European urology, 2025 Jun 25

Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.

Related Topics